SAN DIEGO, June 12 /CNW/ - Nanogen, Inc. (Nasdaq: NGEN), developer of
advanced diagnostic products, announced today that it has received project
funding from several Canadian agencies, including the Canadian Food Inspection
Agency (CFIA). The purpose of the funding and collaborative agreement is to
develop diagnostic tools for the detection of natural or potential bioterror
threats to livestock, such as foot and mouth disease and avian flu, employing
the company's NanoChip(R) platform.
"Although the majority of our NanoChip(R) instruments are used in basic
research and human clinical diagnostics applications, we have always known
that the platform's flexibility confers benefit in other markets, such as
veterinary diagnostics and the monitoring of bioterror threats," said Nanogen
president and chief operating officer David Ludvigson.
Foot and mouth disease, a viral infection that devastated the beef
industry in the United Kingdom in 2001, is a bioterror concern because it is
easily transmissible from animal to animal. Economic losses could be enormous
- the 2001 epidemic cost an estimated $12 billion, according to a study
sponsored by the Wash., D.C.-based Center for Strategic and International
Studies. Avian flu poses a similar threat to poultry stocks.
The NanoChip(R) 400 is the company's second generation automated
multiplexing platform, which uses advanced microarray technology for
performing pathogen sequence detection and genotyping applications. Multiple
samples with multiple targets can be applied to an open and flexible
electronic microarray, the NanoChip cartridge, which may be reused until all
test sites have been utilized. As the NanoChip arrays are built by users
rather than containing pre-determined content, the system provides a simple,
fast and cost effective means for performing molecular testing.
The project, titled "Adaptation of Recently Developed DNA Microarrays to
NanoChip Microarray Technology for Detection of Agroterrorism Agents" was
approved by Defence Research and Development Canada through the CRTI Program
(CBRNE (Chemical, Biological, Radiological, and Nuclear) Research and
Technology Initiative (CRTI). Financial terms were not disclosed. Additional
collaborators include the CFIA's laboratory in Lethbridge, Alberta and the
National Center for Foreign Animal Diseases located in Winnipeg, Manitoba.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose, and
ultimately help treat disease. The company's products include real-time PCR
reagents, the NanoChip(R) electronic microarray platform and a line of rapid
diagnostic tests. Nanogen's ten years of pioneering research involving
nanotechnology holds the promise of miniaturization and continues to be
supported for its potential for diagnostic and biodefense applications. For
additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements, including
whether patents owned or licensed by Nanogen will be developed into products,
whether the patents owned by Nanogen offer any protection against competitors
with competing technologies, whether products under development can be
successfully developed and commercialized, whether results reported by our
customers or partners can be identically replicated, and other risks and
uncertainties discussed under the caption "Factors That May Affect Results"
and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the
Securities and Exchange Commission. These forward-looking statements speak
only as of the date hereof. Nanogen disclaims any intent or obligation to
update these forward-looking statements.
For further information:
For further information: Nanogen, Inc. Robert Saltmarsh, Chief Financial
Officer, 858-410-4600 or Suzanne Clancy, Corporate Communications,